Pfizer is set to release its fourth-quarter and full-year 2025 results on February 3 before market open. According to the Zacks Consensus Estimate, analysts expect fourth-quarter revenues of $16.93 billion and adjusted earnings per share of $0.57. Investors will watch guidance for 2026, especially updates on COVID-19 vaccine demand normalization and performance of key oncology and rare disease franchises. Any revisions to sales trends in Prevnar, Ibrance and the newly approved RSV vaccine could materially affect sentiment ahead of the company’s full-year outlook.

A recent Seeking Alpha commentary cautions that Pfizer’s current valuation may not adequately reflect risks from patent expirations on certain small-molecule therapies and potential pressure from ongoing drug-price negotiations under Medicare. The author, who holds no position in Pfizer, argues that while the company’s dividend track record and free-cash-flow generation remain attractive for income investors, margin headwinds could challenge dividend growth forecasting. This perspective underscores the importance of monitoring pipeline catalysts—such as phase III data for next-generation oncology candidates—and any shifts in U.S. pricing reform debates that could influence Pfizer’s ability to sustain its payout over the long term.